Guanidino-containing drugs in cancer chemotherapy: Biochemical and clinical pharmacology

Biochemical Pharmacology

Volumn 61, Issue 10, 2001, Pages 1183-1193

  Ekelund, Sara ^a   Nygren, Peter ^a   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CHS 828; Cytotoxic activity; Guanidine compounds; MGBG; MIBG; Pharmacology

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 124; (3 IODOBENZYL)GUANIDINE I 131; ADENOSINE TRIPHOSPHATE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CELL DNA; CELL PROTEIN; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; GLUCOSE; GUANIDINE DERIVATIVE; IFOSFAMIDE; METHOTREXATE; MITOGUAZONE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; NORADRENALIN; POLYAMINE DERIVATIVE; SPERMIDINE; UNCLASSIFIED DRUG;

ACIDIFICATION; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER SCINTISCANNING; CELL DEATH; CELL LEVEL; CLINICAL TRIAL; CROSS RESISTANCE; DNA SYNTHESIS INHIBITION; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; GLYCOLYSIS; HUMAN; MITOCHONDRIAL RESPIRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW;

EID: 0035874008     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00570-6     Document Type: Article

References (93)

1. Mitochondrial effects of the guanidino group-containing cytostatic drugs, m-iodobenzylguanidine and methylglyoxal bis (guanylhydrazone)
2. 131I-MIBG therapy of neural crest tumours
3. Polyamines: From molecular biology to clinical applications
4. MGBG: Teaching an old drug new tricks
5. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo
6. 131I]iodobenzylguanidine
7. Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodo-benzylguanidine (MIBG)
8. Synthesis and hypotensive activity of N-alkyl-N″-cyano-N′-pyridylguanidines
9. Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine
10. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: Evidence for uptake-one
11. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells
12. Evaluation of metaiodobenzylguanidine uptake by norepinephrine, dopamine and serotonin transporters
13. Intracellular inhibition of mono(ADP-ribosylation) by meta-iodobenzylguanidine: Specificity, intracellular concentration and effects on glucocorticoid-mediated cell lysis
14. Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging
15. Meta-iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK-N-BE(2c)
16. MIBG causes oxidative stress and up-regulation of anti-oxidant enzymes in the human neuroblastoma cell line SK-N-BE(2c)
17. Meta-iodobenzylguanidine inhibits complex I and III of the respiratory chain in the human cell line Molt-4
18. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)
19. Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG)
20. pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells
21. Potentiation of DNA-adduct formation and cytotoxicity of platinum-containing drugs by low pH
22. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH
23. Reduction of tumor intracellular pH and enhancement of melphalan cytotoxicity by the jonophore nigericin
24. Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia
25. Induction of transient hyperglycaemia in cancer patients
26. pH in human tumor xenografts and transplanted rat tumors: Effect of insulin, inorganic phosphate, and m-iodobenzylguanidine
27. Tumor-specific synergistic therapy of mitomycin C: Modulation of bioreductive activation
28. Enzymology of mitomycin C metabolic activation in tumour tissue: Implications for enzyme-directed bioreductive drug development
29. The interstitial fluid of solid tumors
30. Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: Comparison with m-iodobenzylguanidine
31. Keilin's respiratory chain concept and its chemiosmotic consequences
32. The mitochondrial electron transport and oxidative phosphorylation system
33. MIBG inhibits respiration: Potential for radio- and hyperthermic sensitization
34. Lactate-induced inhibition of tumor cell proliferation
35. Potentiation of glucocorticoid-induced lysis in refractory and resistant leukemia cells by inhibitors of ADP-ribosylation
36. Meta-iodobenzylguanidine (MIBG), a novel high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation)
37. The effect of the neuroblastoma-seeking agent meta-iodobenzylguanidine (MIBG) on NADH-driven superoxide formation and NADH-driven lipid peroxidation in beef heart submitochondrial particles
38. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance
39. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine
40. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors
41. Current concepts on the diagnostic use of MIBG in children
42. Scintigraphic localization of pheochromocytoma
43. Nuclear medicine therapy of pheochromocytoma and paraganglioma
44. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors
45. Radiopharmaceutical treatment of malignant pheochromocytoma
46. New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity
47. Growth inhibition of human osteosarcoma HuO9 cells by methylglyoxal bis(cyclopentylamidinohydrazone) in vitro and in vivo
48. Induction of apoptotic cell death in human hepatocellular carcinoma SK-HEP-1 cells by a polyamine synthesis inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone)
49. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy
50. Polyamine metabolism and function
51. Methylglyoxal-bis(guanylhydrazone) (methyl-GAG): Current status and future prospects
52. What do the polyamines do?
53. Polyamines in rapid growth and cancer
54. Use of aminopropyltransferase inhibitors and of non-metabolizable analogs to study polyamine regulation and function
55. Polyamine metabolism as target for cancer chemoprevention
56. Aspects of the biochemical pharmacology of methyl glyoxal bis(guanylhydrazone)
57. Relation of the antiproliferative action of methylglyoxal-bis(guanylhydrazone) to the natural polyamines
58. 8-spermidine derivatives in cultured L1210 leukemia cells
59. S-Adenosylmethionine decarboxylase as target of chemotherapy
60. Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances
61. Diethylglyoxal bis(guanylhydrazone), a potent inhibitor of mammalian S-adenosylmethionine decarboxylase. Effects on cell proliferation and polyamine metabolism in L1210 leukemia cells
62. Alterations in repair of alkylating agent-induced DNA damage in polyamine-depleted human cells
63. Increased spermidine or spermine levels is essential for hepatocyte growth factor-induced DNA synthesis in cultured rat hepatocytes
64. Mitoguazone induces apoptosis via p53-independent mechanism
65. The generality of methylglyoxal bis(guanylhydrazone)-induced mitochondrial damage and the dependence of this effect on cell proliferation
66. Inhibition by derivatives of diguanidines of cell proliferation in Ehrlich ascites cells grown in culture
67. The possible role of intracellular polyamines in mitochondrial metabolic regulation
68. Independence of drug action on mitochondria and polyamines in L1210 leukemia cells treated with methylglyoxal-bis(guanylhydrazone)
69. Protective action of methylglyoxal bis (guanylhydrazone) on the mitochondrial membrane
70. Enhanced uptake of spermidine and methylglyoxal-bis(guanylhydrazone) by rat liver mitochondria following outer membrane lysis
71. Actions of bis(guanylhydrazones) on isolated rat liver mitochondria
72. Carcinostatic action of polycarbonyl compounds and their derivatives. II. Glyoxal bis(guanylhydrazone) and derivatives
73. Methyl glyoxal bis(guanylhydrazone) as a potent inhibitor of mammalian and yeast S-adenosylmethionine decarboxylases
74. Polyamines regulate human medullary thyroid carcinoma TT-cell proliferation and secretion of calcitonin and calcitonin gene-related peptide
75. The effects of methylglyoxal-bis(guanylhydrazone) on spermine binding and transport in liver mitochondria
76. Spermidine binding to liver mitochondria
77. Pharmacokinetic profile of mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma
78. Phase II trials of methylglyoxal-bis(guanylhydrazone)
79. Clinical drug development: An analysis of phase II trials, 1970-1985
80. Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: An Eastern cooperative oncology group study (PE481)
81. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multicenter phase II trial
82. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: A Swedish national prospective study
83. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: A prospective study
84. Combination therapy with mitoguazone, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
85. Novel cyanoguanidines with potent oral antitumour activity
86. Chemotherapeutic drug sensitivity testing of leukaemic cells in vitro using a semiautomated fluorometric assay
87. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphocytic leukemia
88. Localization of the primary metabolic block produced by 2-deoxyglucose
89. Carbohydrate metabolism in cultured animal cells
90. Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis
91. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats